These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
534 related items for PubMed ID: 16921043
1. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hänel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U. J Clin Oncol; 2006 Aug 20; 24(24):3919-26. PubMed ID: 16921043 [Abstract] [Full Text] [Related]
2. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J, Anglo-Celtic Cooperative Oncology Group. J Natl Cancer Inst; 2004 Jul 21; 96(14):1076-83. PubMed ID: 15265969 [Abstract] [Full Text] [Related]
3. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG. Clin Cancer Res; 1999 Nov 21; 5(11):3411-8. PubMed ID: 10589752 [Abstract] [Full Text] [Related]
4. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle. Bashey A, Corringham S, Garrett J, Lane TA, Gilpin EA, Corringham RE, Law P, Ho AD. Bone Marrow Transplant; 2000 Mar 21; 25(5):519-24. PubMed ID: 10713629 [Abstract] [Full Text] [Related]
5. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L. Bone Marrow Transplant; 2001 Feb 21; 27(3):269-78. PubMed ID: 11277174 [Abstract] [Full Text] [Related]
7. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S. Bone Marrow Transplant; 2001 Jul 21; 28(2):173-80. PubMed ID: 11509935 [Abstract] [Full Text] [Related]
8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ. Biol Blood Marrow Transplant; 2004 Jun 21; 10(6):395-404. PubMed ID: 15148493 [Abstract] [Full Text] [Related]
10. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. J Clin Oncol; 2006 Aug 20; 24(24):3865-70. PubMed ID: 16864853 [Abstract] [Full Text] [Related]
11. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment. Klumpp TR, Goldberg SL, Magdalinski AJ, Mangan KF. Bone Marrow Transplant; 1997 Aug 20; 20(4):273-81. PubMed ID: 9285541 [Abstract] [Full Text] [Related]
12. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer. deMagalhaes-Silverman M, Bloom E, Lembersky B, Lister J, Pincus S, Rybka W, Voloshin M, Wilson J, Ball E. Clin Cancer Res; 1997 Feb 20; 3(2):193-7. PubMed ID: 9815672 [Abstract] [Full Text] [Related]
13. [High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer]. Martín M, Casado A, Llorente L, López Martín JA, Rodríguez Lescure A, Nieto Y, Ayala F, Pérez Calvo J, Alonso JL, Pérez López C, Villegas A, Díaz-Rubio E. Med Clin (Barc); 1997 Dec 06; 109(20):775-81. PubMed ID: 9493155 [Abstract] [Full Text] [Related]
14. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. J Clin Oncol; 2006 Feb 20; 24(6):929-36. PubMed ID: 16432076 [Abstract] [Full Text] [Related]
15. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Cancer; 2006 Jun 01; 106(11):2327-36. PubMed ID: 16639731 [Abstract] [Full Text] [Related]
16. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M, Possinger K. J Clin Oncol; 2005 Jan 20; 23(3):432-40. PubMed ID: 15659490 [Abstract] [Full Text] [Related]
17. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bitran JD, Samuels B, Klein L, Hanauer S, Johnson L, Martinec J, Harris E, Kempler J, White W. Bone Marrow Transplant; 1996 Feb 20; 17(2):157-62. PubMed ID: 8640160 [Abstract] [Full Text] [Related]
18. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer. Bilgrami S, Feingold JM, Bona RD, Edwards RL, Khan AM, Rodriguez-Pinero F, Khan IA, Kazierad D, Clive J, Tutschka PJ. Bone Marrow Transplant; 2000 Jan 20; 25(2):123-30. PubMed ID: 10673668 [Abstract] [Full Text] [Related]
19. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study. Toh HC, McAfee SL, Sackstein R, Multani P, Cox BF, Garcia-Carbonero R, Colby C, Spitzer TR. Bone Marrow Transplant; 2000 Jan 20; 25(1):19-24. PubMed ID: 10654009 [Abstract] [Full Text] [Related]
20. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P. J Natl Cancer Inst; 2005 Dec 07; 97(23):1724-33. PubMed ID: 16333028 [Abstract] [Full Text] [Related] Page: [Next] [New Search]